Alnylam Pharmaceuticals (ALNY) Share-based Compensation (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Share-based Compensation data on file, last reported at $70.2 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 23.7% year-over-year to $70.2 million; the trailing twelve-month figure through Mar 2026 stood at $361.7 million (up 27.6% YoY), and the FY2025 full-year result was $348.2 million, up 27.99% from the prior year.
• Share-based Compensation for Q1 2026 stood at $70.2 million, down from $71.6 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $128.1 million in Q3 2022 and bottomed at $29.3 million in Q1 2022.
• The 5-year median for Share-based Compensation is $63.9 million (2023), against an average of $67.2 million.
• The widest annual swing landed in 2022, when Share-based Compensation jumped 283.97%; it then plunged 50.1% in 2023.
• A 5-year view of Share-based Compensation shows it stood at $42.8 million in 2022, then decreased by 1.81% to $42.0 million in 2023, then jumped by 118.23% to $91.6 million in 2024, then decreased by 21.84% to $71.6 million in 2025, then retreated by 2.06% to $70.2 million in 2026.
• The last three Share-based Compensation figures came in at $70.2 million (Q1 2026), $71.6 million (Q4 2025), and $108.2 million (Q3 2025), per Business Quant data.

Peer Comparison